Century Therapeutics, Inc. (IPSC) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -116.99M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-116.99M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $-115.13M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $-17.27M | $109.16M | (m) | (m) | (m) | -15.82% |
| 2025-09-30 | $-33.90M | $113.34M | (m) | (m) | (m) | -29.91% |
| 2025-06-30 | $-32.56M | $114.13M | (m) | (m) | (m) | -28.53% |
| 2025-03-31 | $-32.65M | $114.90M | (m) | (m) | (m) | -28.42% |
| 2024-12-31 | $-138.14M | $6.59M | (m) | (m) | (m) | -2096.48% |
| 2024-09-30 | $-144.62M | $2.68M | (m) | (m) | (m) | -5388.04% |
| 2024-06-30 | $-145.46M | $2.04M | (m) | (m) | (m) | -7126.70% |
| 2024-03-31 | $-145.77M | $1.37M | (m) | (m) | (m) | -10640.44% |
| 2023-12-31 | $-146.55M | $2.23M | (m) | (m) | (m) | -6556.87% |
| 2023-09-30 | $-136.09M | $2.49M | (m) | (m) | (m) | -5469.86% |
| 2023-06-30 | $-132.20M | $4.56M | (m) | (m) | (m) | -2896.63% |
| 2023-03-31 | $-128.48M | $5.86M | (m) | (m) | (m) | -2192.05% |
| 2022-12-31 | $-133.83M | $5.20M | (m) | (m) | (m) | -2574.17% |
| 2022-09-30 | $-128.50M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-122.59M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-114.26M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-94.88M | (m) | (m) | $75.65M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-53.90M | (m) | (m) | $39.68M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |